- Home
- NRDS vs ANL Comparison
NRDS vs ANL Comparison
Compare NRDS & ANL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | NRDS | ANL |
|---|---|---|
| Founded | 2009 | 2004 |
| Country | United States | Cayman Islands |
| Employees | N/A | N/A |
| Industry | EDP Services | |
| Sector | Technology | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 720.4M | 703.3M |
| IPO Year | 2021 | 2022 |
Fundamental Metrics
Financial Performance| Metric | NRDS | ANL |
|---|---|---|
| Price | $10.93 | $12.78 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 6 | 1 |
| Target Price | $14.33 | ★ $20.00 |
| AVG Volume (30 Days) | 435.8K | ★ 693.8K |
| Earning Date | 05-06-2026 | 04-10-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 68.42 | N/A |
| EPS | ★ 0.64 | N/A |
| Revenue | ★ $836,600,000.00 | N/A |
| Revenue This Year | $10.13 | $36.02 |
| Revenue Next Year | $7.11 | N/A |
| P/E Ratio | $17.33 | ★ N/A |
| Revenue Growth | ★ 21.67 | N/A |
| 52 Week Low | $8.34 | $0.88 |
| 52 Week High | $16.24 | $17.25 |
Technical Indicators
Market Signals| Indicator | NRDS | ANL |
|---|---|---|
| Relative Strength Index (RSI) | 54.02 | 51.89 |
| Support Level | $10.14 | $1.36 |
| Resistance Level | $11.07 | $17.25 |
| Average True Range (ATR) | 0.33 | 2.49 |
| MACD | 0.03 | -0.31 |
| Stochastic Oscillator | 62.31 | 53.68 |
Price Performance
Historical ComparisonAbout NRDS NerdWallet Inc.
Nerdwallet Inc is a company that provides consumer-driven advice about personal finance through its platform by connecting individuals and small and mid-sized businesses (SMBs) with providers of financial products. The Company's platform comprises three primary components: Editorial and Content Publishing, Marketplace and Referral Services, and Financial Services. It operates in the United States, Canada, and the United Kingdom.
About ANL Adlai Nortye Ltd.
Adlai Nortye Ltd is a clinical-stage biotechnology company focused on the discovery and development of cancer therapies for patients across the spectrum of tumor types. The company has a robust pipeline of drug candidates which includes buparlisib (AN2025), palupiprant (AN0025), and AN4005 in the clinical stage, and AN8025, AN9025, and AN1025 in the preclinical stage.